Evogene (XTAE:EVGN) Beginning Cash Position : ₪76.96 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Evogene Beginning Cash Position?

Evogene's Beginning Cash Position for the quarter that ended in Mar. 2024 was ₪76.96 Mil.

Evogene's quarterly Beginning Cash Position increased from Sep. 2023 (₪74.96 Mil) to Dec. 2023 (₪101.26 Mil) but then declined from Dec. 2023 (₪101.26 Mil) to Mar. 2024 (₪76.96 Mil).

Evogene's annual Beginning Cash Position declined from Dec. 2021 (₪171.27 Mil) to Dec. 2022 (₪119.76 Mil) and declined from Dec. 2022 (₪119.76 Mil) to Dec. 2023 (₪107.37 Mil).

Evogene Beginning Cash Position Historical Data

The historical data trend for Evogene's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Beginning Cash Position Chart

Evogene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

21.53

128.74

171.27

119.76

107.37

Evogene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															107.37	85.21	74.96	101.26	76.96

Evogene Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Evogene Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Evogene's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Evogene (XTAE:EVGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

EVGN:USA

Address

13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002

Website

https://www.evogene.com

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.